Financial Performance - The revenue for the year ended December 31, 2021, was approximately RMB 72,864,000, representing a year-on-year increase of 6.6% compared to RMB 68,340,000 for the prior year[18]. - Revenue from the Taiwan market decreased to approximately RMB 1,450,000, a year-on-year decline of 32.5% from RMB 2,148,000 due to strict pandemic control measures[21]. - In Hong Kong, revenue from funeral arrangement and related consultancy services increased to approximately RMB 892,000, representing a year-on-year growth of 82.8% from RMB 488,000[21]. - The Group's revenue from the PRC market increased by 14.6% year-on-year to approximately RMB 70,294,000 from RMB 61,317,000 in the prior year[48]. - Revenue from funeral, cremation, and cemetery services in the PRC contributed approximately RMB 69,561,000, up from RMB 60,961,000 in the prior year[49]. - Revenue from Vietnam decreased by approximately 47.6% to RMB 228,000 from RMB 435,000 in the prior year[57]. - Gross profit for the year was approximately RMB 37,977,000, a year-on-year increase of 30.2%, with a gross profit margin of approximately 52.1% compared to 42.7% in the prior year[68]. - The increase in gross profit was mainly driven by the funeral services in China, which rebounded from the impact of COVID-19[68]. - The Group's funeral services in the PRC rebounded from the impact of COVID-19, benefiting from the recovery of economic activities[50]. - Loss attributable to the owners of the Company for the year was approximately RMB 9,872,000, compared to RMB 2,974,000 in the prior year, with loss per share of approximately RMB 1.33 cents[77]. Business Strategy and Focus - The Group's business pattern focuses on traditional funeral services and emerging biotechnology, with traditional funeral services accounting for a large proportion of the Group's business[18]. - The Group is focusing on biotechnology as a long-term business expansion strategy, particularly in stem cells and advanced biotechnical equipment[23]. - A specialized investment platform was established in December 2021 to promote the rapid development of the biotechnology business, focusing on biomedicine, medical healthcare, and life science instruments[25]. - The Group aims to allocate more resources to support the development of its biotechnology business while consolidating its traditional funeral services[26]. - The Group plans to reduce investments in the stem cell business in the short term due to the lack of large-scale development opportunities in Mainland China[23]. - The Group aims to expand its advanced biotechnical equipment business by leveraging opportunities in the rapidly developing electron microscope industry in Mainland China[42]. - The Group positions Zhongke Zhenhui as a specialized investment platform for biotechnology development, including biomedicine and medical healthcare[104]. - The Group will continue to monitor the impact of the COVID-19 pandemic on its financial position and operating results[79]. Economic Environment - China's GDP reached RMB 114.4 trillion in 2021, with a real GDP growth rate of 8.1%[17]. - The economic development in China is led by strategic emerging industries such as new energy, intelligent manufacturing, biomedicine, and semiconductors[17]. - The Chinese government established the Beijing Stock Exchange in November 2021 to expand financing channels for small and medium-sized enterprises, promoting innovative development in emerging industries[36]. - The ongoing COVID-19 pandemic continues to create uncertainty in the global economic environment, affecting customer spending and business operations[98]. - The strategic goals of supporting emerging industries and promoting high-quality economic development in China remain unchanged despite economic pressures[102]. Corporate Governance - The Company will review its corporate governance practices to ensure compliance with statutory requirements and the GEM Listing Rules[116]. - The Company emphasizes the importance of management reporting to the Board before making significant decisions or commitments[128]. - The Board has established three committees: Audit Committee, Remuneration Committee, and Nomination Committee, each with defined terms of reference[150]. - The Company has maintained compliance with GEM Listing Rules regarding Directors' securities transactions throughout the year[120]. - The Board consists of six Directors, demonstrating diversity in age, service length, educational background, and professional experience[198]. - The Nomination Committee believes the current Board composition meets measurable objectives for achieving diversity[200]. Human Resources - The Group employed approximately 171 employees as of December 31, 2021, a decrease from 179 employees in the prior year[91]. - The Group will implement various incentives to attract and retain top talents to improve operational conditions and enhance profitability[111]. - The attendance record for Directors at meetings indicates full participation from executive Directors[136]. Financial Position - As of December 31, 2021, the Group had cash and bank balances of approximately RMB 117,557,000, with current and non-current bank borrowings of approximately RMB 1,192,000 and RMB 4,812,000 respectively[77]. - The gearing ratio as of December 31, 2021, was approximately 2.3%, a slight decrease from 2.5% in the prior year[77]. - The Group did not use any financial instruments for hedging purposes during the year, maintaining a prudent financial management strategy[77]. - The Group's capital expenditure for property, plant, and equipment in 2021 amounted to approximately RMB 1,303,000, down from RMB 3,713,000 in the prior year[95]. - The Group's financial condition may be affected by changes in exchange rates of RMB against USD, NTD, HKD, and VTD[79].

THIRD QUARTERLY REPORT 2021 活出精彩 LIVE LIFE TO THE FULLEST 第三季度報告 2021 活出精彩 LIVE LIFE TO THE FULLEST 香港聯合交易所有限公司（「聯交所」）GEM之特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 告共同及個別承擔全部責任。 事實致使本報告或其所載任何陳述產生誤導。 01 第三季 季度報告 2021 c_212380 (Sino-Life_3Q).indd 1 15/11/2021 10:55:42 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣的證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 本報告乃遵照聯交所GEM ...

SINO-LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 於開曼群岛註冊成立的有限公司 取合代號:8296 202 ] 中期業績報告 F 活出精彩 LIVE LIFE TO THE FULLEST 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董 ...

FIRST QUARTERLY REPORT 2021 | --- | |-------| | | | | 第一季度報告 2021 | --- | --- | --- | --- | --- | |-------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在 ...

8 於開發群島註冊成立的有限公司 股份代號:8296 JLLEST SINO LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 2020 第三季度報告 H2( 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料；本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所 ...

IDIE 09 SINO-LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 於開發群島註票成立的有限公司 股份代號 : 8296 2020 中期最新版告 HPC 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及 ...

nH2 | --- | --- | --- | --- | --- | --- | |----------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | SINO-LIFE GROUP LIMITED中 國 生 命 集 團 有 限 公 司 | | | | | | Stock Code 股份代號 : 8296 | Incorporated in the Cayman Islands with limited liability 於閉曼群 ...

ES g SINO-LIFE GROUP LIMITED 中 國 生 命 集 團 有 限 公 司 於開發群島註票成立的有限公司 股份代號 : 8296 2020 * HSC 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在聯交所上市的公司帶有較高投資風險。有意投資的人士應了解投資於該 等公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料；本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其所知及所信，本報告所載 ...

活出精彩 Live life to the Fullest Third Quarterly Report 2019 活出精彩 Live life to the Fullest 第三季度報告2019 香港聯合交易所有限公司（「聯交所」）GEM的特色 GEM的定位，乃為中小型公司提供一個上市的市場，此等公司相比起其他 在主板上市的公司帶有較高投資風險。有意投資的人士應了解投資於該等 公司的潛在風險，並應經過審慎周詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板 買賣之證券承受較大的市場波動風險，同時無法保證在GEM買賣的證券會 有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告之內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示概不就因本報告全部或任何部 分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載， 旨在提供有關中國生命集團有限公司（「本公司」）的資料。本公司的董事（「董 事」）願就本報告的資料共同及個別地承擔全部責任。 各董事在作出一切合理查詢後，確認就其 ...

Financial Performance - For the six months ended June 30, 2019, the company reported total revenue of RMB 31,705,000, an increase of 0.62% compared to RMB 31,509,000 for the same period in 2018[7]. - The gross profit for the same period was RMB 16,047,000, representing a gross margin of 50.6%, compared to RMB 15,309,000 and a gross margin of 48.7% in 2018[7]. - The company incurred a loss of RMB 1,969,000 for the six months ended June 30, 2019, an improvement from a loss of RMB 2,577,000 in the prior year[9]. - Basic and diluted loss per share for the six months was RMB 0.03, compared to a loss of RMB 0.39 per share in the same period of 2018[9]. - The total comprehensive income for the period, after tax, was RMB 622,000, compared to RMB 3,406,000 in the previous year[9]. - The company reported a net profit before tax of RMB 201 thousand for the six months ended June 30, 2019, a significant recovery from a loss of RMB 2,504 thousand in the same period of 2018[62]. - The group recorded a profit attributable to owners of approximately RMB 242,000, compared to a loss of RMB 2,869,000 in the previous period, resulting in earnings per share of RMB 0.03 compared to a loss of RMB 0.39 per share previously[143]. Cash Flow and Liquidity - Cash and cash equivalents as of June 30, 2019, amounted to RMB 115,764,000, a decrease from RMB 205,272,000 at the end of 2018[12]. - The company reported a net cash outflow from operating activities of RMB (2,565) thousand for the six months ended June 30, 2019, compared to RMB (2,364) thousand for the same period in 2018[22]. - The net cash inflow from investing activities was RMB 14,146 thousand for the six months ended June 30, 2019, compared to a net outflow of RMB (437) thousand in 2018[22]. - The company experienced a net cash outflow from financing activities of RMB (355) thousand in the first half of 2019, an improvement from RMB (967) thousand in the same period of 2018[22]. - The total cash and cash equivalents increased by RMB 11,226 thousand to RMB 115,764 thousand as of June 30, 2019, compared to RMB 101,345 thousand at the end of June 2018[22]. - The group maintained a healthy financial position with cash and bank balances of approximately RMB 115,764,000 as of June 30, 2019, up from RMB 103,467,000 at the end of 2018[145]. Assets and Liabilities - The company's total assets less current liabilities stood at RMB 149,700,000, an increase from RMB 111,043,000 in the previous year[12]. - The company’s total liabilities as of June 30, 2019, were RMB (161,984) thousand, reflecting a significant increase from RMB (153,297) thousand in the previous year[18]. - The total assets of the company as of June 30, 2019, were RMB 255,074 thousand, up from RMB 227,661 thousand as of December 31, 2018, showing an increase of approximately 12.06%[59]. - The total liabilities increased to RMB 160,228 thousand as of June 30, 2019, from RMB 123,818 thousand at the end of 2018, marking a rise of about 29.43%[59]. - The company’s lease liabilities include both current and non-current portions, with current lease liabilities amounting to RMB 4,178,000 and non-current lease liabilities at RMB 38,249,000[47]. Business Strategy and Future Outlook - The company plans to focus on expanding its market presence and enhancing its product offerings in the upcoming periods[6]. - The company is focused on expanding its services in the funeral and related sectors, as well as in the sale of burial plots and tombstones, which are key areas for future growth[24]. - The company has introduced a new business segment focused on stem cell and immune cell services, which is expected to be a major value driver[54]. - The company plans to continue its focus on the funeral business while actively developing the cell industry through various investment collaborations[157]. - The company aims to create value for shareholders by seeking new business opportunities and optimizing its business structure for sustainable growth[157]. Accounting and Financial Reporting - The board of directors confirmed that the financial information presented is accurate and complete, with no misleading elements[2]. - The adoption of Hong Kong Financial Reporting Standard 16 resulted in an increase of RMB 31,513 thousand in right-of-use assets and a total lease liability of RMB 40,363 thousand as of June 30, 2019[36]. - The financial impact of HKFRS 16 did not have a significant effect on the earnings per share for the period[38]. - The total equity decreased by RMB 11,648 thousand due to the adjustments made under HKFRS 16[36]. - The audit committee, composed of three independent non-executive directors, reviewed the financial statements for the six months ended June 30, 2019, and confirmed compliance with applicable accounting standards[188]. Revenue Breakdown - The revenue from funeral services was RMB 29,958 thousand, an increase from RMB 29,234 thousand in the previous year, reflecting a growth of about 2.48%[74]. - The revenue from stem cell and immune cell sales was RMB 301 thousand for the six months ended June 30, 2019, compared to no revenue in the same period of 2018[67]. - Revenue from the sale of burial plots and tombstones was RMB 175 thousand for the six months ended June 30, 2019, up from RMB 123 thousand in the same period of 2018, indicating a growth of approximately 42.24%[67]. - The group's revenue from the Chinese funeral services business increased by approximately 2.5% compared to the same period last year, reaching RMB 29,958,000, which accounts for 94.5% of total revenue[134]. - Revenue from the Taiwan market decreased by approximately 8.3%, totaling RMB 1,308,000, representing 4.1% of total revenue[139]. - Revenue from the Hong Kong market saw a significant decline of 63.2%, amounting to RMB 264,000, which is 0.8% of total revenue[139]. Cost Management - Employee costs, including director remuneration, rose to RMB 9,583,000 for the six months ended June 30, 2019, up from RMB 7,991,000 in 2018, reflecting a 20% increase[79]. - Sales costs decreased by approximately 3.3% to about RMB 15,658,000 from RMB 16,200,000, attributed to cost control measures in funeral services[142]. - Administrative expenses were approximately RMB 9,484,000, down about 15.8% from RMB 11,261,000, reflecting effective cost control measures[142]. Shareholder Information - As of June 30, 2019, Hong Kong Gaoqi holds 220,475,000 shares, representing approximately 29.69% of the company's issued share capital[160]. - The weighted average number of ordinary shares for the six months ended June 30, 2019, remained unchanged at 742,500,000 shares[91]. - The stock option plan allows for a maximum of 74,250,000 shares to be issued, equivalent to 10% of the total issued shares as of the mid-term report date[171]. - The total number of shares that may be issued under the stock option plan and any other plans shall not exceed 30% of the total issued shares at any time[173].